SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Importance Weight loss improves cardiometabolic risk factors in people with overweight or
obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective …

Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …

Diabetes mellitus is a major public health problem, affecting about 10% of the population.
Pharmacotherapy aims to protect against microvascular complications, including blindness …

Aim To investigate the effects of once‐weekly subcutaneous (sc) semaglutide 2.4 mg on
gastric emptying, appetite, and energy intake in adults with obesity. Materials and Methods A …